This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
After successfully leveraging the ongoing craze around weight loss drugs that leverage a GLP-1 agonist to offer better efficacy, Eli Lilly and Company (LLY) seems to have turned its gaze toward combating drug-resistant pathogens. What's more, the pharma giant has partnered with one of the biggest AI names for this endeavor.
To wit, Eli Lilly and Company has announced that it is partnering with OpenAI to create "novel antimicrobials" for drug-resistant pathogens.
Antimicrobial Resistance (AMR) is a particularly grave concern in low- and middle-income countries, where the excessive use of antimicrobials and antibiotics in humans, animals, and plants is giving rise to a new breed of drug-resistant pathogens.
Diogo Rau, Eli Lilly and Company's executive vice president and chief information and digital officer, noted in the press release:
"Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance."
He goes on to note:
"Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens."
Of course, Eli Lilly and Company has long eyed AMR as an important vector in its expanding product portfolio. Back in 2020, the pharma giant committed $100 million via its Social Impact Venture Capital Portfolio to the AMR Action Fund, which aims to create between 2 and 4 new antibiotics by 2030.
For the benefit of those who might not be aware, Eli Lilly and Company is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly.
Eli Lilly and Company offers Tirzepatide as one of its proprietary drugs to combat diabetes and obesity. The drug leverages a GLP-1 agonist and a Glucose-dependent Insulinotropic Polypeptide (GIP) one to ensure improved efficacy. Eli Lilly markets Tirzepatide under the Mounjaro and Zepbound labels, with the former geared toward diabetes and the latter billed as a treatment for obesity.
About the author: Writing is my one incontrovertible passion. Over the past six years, he has authored over 2,200 distinct articles on financial and tech-related topics, spanning nearly 1 million words. And he has been a member of Wcctech mobile team since 2025. As an alumnus of the University of Toronto, Rotman Commerce Program, I bring nuance, in-depth knowledge, and a unique perspective to every topic that I cover. When I'm not writing, I'm traveling the world, exploring hidden confectionaries and restaurants as an aspiring food connoisseur.
Follow Wccftech on Google to get more of our news coverage in your feeds.
